For citations:
Lokyan L.A., Ganshina I.P., Sorokina I.V., Lubennikova E.V., Bagrova S.G., Zhukova L.G., Filonenko D.A., Gordeeva O.O., Lezina K.S., Artamonova E.V. Long-acting G-CSF empegfilgrastim with dose-dense chemotherapy for patients with stage II–III TNBC: Defendor Special trial, primary analysis. Medical alphabet. 2025;(14):53-59. (In Russ.) https://doi.org/10.33667/2078-5631-2025-14-53-59
Email this article 